Cannabidiol 1 is under clinical development by Cardiol Therapeutics and currently in Phase II for Pericarditis. According to GlobalData, Phase II drugs for Pericarditis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Cannabidiol 1 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cannabidiol 1 overview
Cannabidiol is under development for the treatment of diastolic heart failure, myocardial fibrosis, acute myocarditis and recurrent pericarditis. The drug candidate was under development for the treatment of hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). It acts by targeting cannabinoid receptors (CB1 and CB2). It is developed based on the proprietary nanotechnology platform. It is administered through oral route and subcutaneous.
Cardiol Therapeutics overview
Cardiol Therapeutics (Cardiol) is a company that develops and manufactures cannabidiol products and therapies to treat heart diseases. Its lead product candidate CardiolRx is used to treat inflammatory heart diseases. It is also evaluating therapies against acute myocarditis and heart failure. Cardiol is developing its proprietary nanotherapeutics technology to deliver pharmaceutical cannabidiol and other anti-inflammatory drugs directly to sites of inflammation in the heart. It works in partnership with DeBakey Heart and Vascular Center, University of Alberta, Dalton Pharma Services and other companies to research and manufacture its products. Cardiol is headquartered in Oakville, Ontario, Canada.
For a complete picture of Cannabidiol 1’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
